Immune Interventions in New-Onset Type 1 Diabetes
Two studies and an editorial explore the use of Janus kinase (JAK) inhibitors for preserving pancreatic β-cell function and preventing disease progression in type 1
Two studies and an editorial explore the use of Janus kinase (JAK) inhibitors for preserving pancreatic β-cell function and preventing disease progression in type 1
A review article reports that an increasing number of agents that affect the complement system are in development, including some for common diseases. While many
In the PROTECT phase 3 trial, the novel, nonimmunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist sparsentan significantly reduced proteinuria and preserved kidney function in patients
In the Sarilumab in Patients with Polymyalgia Rheumatica (SAPHYR) trial, interleukin-6 blockade with the monoclonal antibody “showed significant efficacy in achieving sustained remission and reducing the
Revaccination of people who had previous allergic reactions to COVID-19 vaccines is addressed in a guidance update of the 2021 GRADE (Grading of Recommendations Assessment,
Authors of a review article describe how low-grade inflammation in patients with obesity plays a role in the development of other immunological diseases, including cancers
In a phase 3, placebo-controlled trial of adults with primary immunoglobulin A (IgA) nephropathy, a formulation of targeted-release budesonide (Nefecon) reduced the decline in estimated
Among immunocompromised patients hospitalized for COVID-19, “prompt initiation of remdesivir … is associated with significant survival benefit across all variant waves,” researchers report. “These findings
Routine removal of the thymus during unrelated surgical procedures should be reconsidered in light of a study showing worse health outcomes after thymectomy. All-cause mortality
Patients with disabling pansclerotic morphea (DPM) caused by gain-of-function variants in the gene for signal transducer and activator of transcription (STAT) 4 (STAT4) responded to ruxolitinib therapy, a